Lexicon Pharmaceuticals, Inc.'s FY2025 CEO total of $3.6M ranks #1040 of 1,423 complete filings; its 13:1 pay ratio ranks #1259. Dollar rank is not ratio rank.
According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $282,707. Industry placement uses the FY2025 SIC-28 peer cohort (#
137 of 168, 19th percentile - among the lower quartile of industry peers by pay ratio).
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates.
View all Chemicals & Pharmaceuticals companies.
Dollar rank
#1040
$3.6M of 1,423 FY2025
Ratio rank
#1259
13:1 of 1,423
Industry pct
19th
among the lower quartile of industry peers by pay ratio
How Lexicon Pharmaceuticals, Inc. ranks nationally
Lexicon Pharmaceuticals, Inc. CEO pay vs. every FY2025 complete filing
Total CEO compensation, the full national distribution, this company marked
$3,553,95327th percentilehigher than 27% of 1,423 companies
Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Lexicon Pharmaceuticals, Inc. vs. Chemicals & Pharmaceuticals peers
CEO total pay ($3.6M) against pay ratio (13:1) for Lexicon Pharmaceuticals, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.
Lexicon Pharmaceuticals, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.
Lexicon Pharmaceuticals, Inc.: CEO total $3.6M, pay ratio 13:1:1.
Lifecore Biomedical, Inc. \de\: CEO total $6.5M, pay ratio 12:1:1.
Puma Biotechnology, Inc.: CEO total $3.1M, pay ratio 11:1:1.
Relay Therapeutics, Inc.: CEO total $4.6M, pay ratio 15:1:1.
Cumberland Pharmaceuticals Inc: CEO total $101K, pay ratio 10:1:1.
Acadia Pharmaceuticals Inc: CEO total $2.6M, pay ratio 9:1:1.
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
A component-level pay breakdown is not reported in Lexicon Pharmaceuticals, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · Lexicon Pharmaceuticals, Inc.
Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
Latest ratio
13:1
FY2025
vs prior FY
+3:1
from FY2024 10:1
CEO $ YoY
+25%
$3.6M latest
Filings shown
5
FY2021–2025
Lexicon Pharmaceuticals, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY
CEO pay
Δ pay
Median worker
Pay ratio
Δ ratio
2021
$3.9M
-
$234,672
17:1
-
2022
$4.2M
+6.3%
$243,342
17:1
0:1
2023
$4.1M
-1.4%
$206,303
20:1
+3:1
2024
$2.8M
-31%
$304,524
10:1
-10:1
2025
$3.6M
+25%
$282,707
13:1
+3:1
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1062822, FY2021–2025. Adjacent-year deltas only.
Lexicon Pharmaceuticals, Inc.: near-parity Item 402(u) ratio
Lexicon Pharmaceuticals, Inc.'s FY2025 ratio 13:1 ranks #137 of 168 Chemicals & Pharmaceuticals filers (19th percentile). the CEO earned 13× the median employee ($282,707) in FY2025.
At $282,707 median worker pay, the FLOOR stamp is near pay-parity territory under MID$ CEO total.
CEO Total Pay
$3.6M
FY2025 Summary Compensation, below median
Pay Ratio
13:1
Below typical
Lexicon Pharmaceuticals, Inc. in the lower Chemicals & Pharmaceuticals third
Lexicon Pharmaceuticals, Inc.'s FY2025 ratio 13:1 ranks #137 of 168 Chemicals & Pharmaceuticals filers (19th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Lexicon Pharmaceuticals, Inc.'s $3.6M CEO total is at or below the $7.9M industry median CEO pay.
SEC EDGAR DEF 14A for CIK 1062822, FY2025. Informational only, not investment advice. Verify on EDGAR.
Read our methodology
- how this data is sourced, computed, and verified.
Lexicon Pharmaceuticals, Inc.'s FY2025 ratio 13:1 ranks #137 of 168 Chemicals & Pharmaceuticals filers (19th percentile).
Read with Lexicon Pharmaceuticals, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip.
This page stamps FLOOR · MID$ · ELITE-MED.
Data sourced from SEC EDGAR DEF 14A for Lexicon Pharmaceuticals, Inc. (CIK 1062822), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency:
Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology
for source dates and refresh cadence. Spot a figure that looks wrong?
Report a correction.
P
Compiled by PlainCEOPay, CEO compensation data publisher